When was Ascend founded?

Ascend was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Ascend located?

Ascend is headquartered in London, United Kingdom. It is registered at 3RD FLOOR,1 ASHLEY ROAD,ALTRINCHAM,CHESHIRE,UNITED KINGDOM,WA14 2DT.

How many employees does Ascend have?

As of Sep 30, 2026, the latest employee count at Ascend is 99.

Is Ascend a funded company?

Ascend is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Mar 01, 2023.

When was the latest funding round of Ascend?

Ascend's latest funding was a $***** Series A round on Mar 01, 2023, with participation from 8 investors.

Where does Ascend rank among its competitors?

Ascend ranks 15th amongst 142 active competitors, of which 27 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was XDemics, which secured $7.4M in Oct, 2025.

Who are the top competitors of Ascend?

Ascend's top competitors include Blue Rock Therapeutics, CellCarta and Invivyd. Among them, XDemics secured the most recent funding round in October, 2025.

Ascend - 2026 Company Profile, Funding & Competitors

Company Details

Website: ascend-gctx.com
Registered Address: 3RD FLOOR,1 ASHLEY ROAD,ALTRINCHAM,CHESHIRE,UNITED KINGDOM,WA14 2DT

Key Metrics

Founded Year

2021

Location

London, United Kingdom

Stage

Series A

Total Funding

$132M in 1 round

Latest Funding Round

Series A, Mar 01, 2023, $*****

Investors

Abingworth & 8 more

Ranked

15^th among 142 active competitors

Employee Count

99 as on Sep 30, 2026

Similar Companies

Blue Rock Therapeutics & 149 more

View Ascend's full profile

Ascend is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Ascend Gene And Cell Therapies Ltd CIN: 13471083 , United Kingdom, Active	Jun 21, 2021	-	-

Ascend has raised a total funding of $132M over 1 round. Its latest funding round was a Series A round on Mar 01, 2023 for $*****. 8 investors participated in its latest round. Ascend has 9 institutional investors.

Here is the list of recent funding rounds of Ascend:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2023	1442336	Series A	7924513	2491644	9627977	3213249

Access funding benchmarks and valuations. Sign up today!

View details of Ascend's funding rounds and investors

Ascend's employee count trend

Ascend has 99 employees as of Sep 26. Here is Ascend's employee count trend over the years:

Uncover Ascend's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ascend include Blue Rock Therapeutics, CellCarta and Invivyd. Here is the list of Top 10 competitors of Ascend, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	64/100
2nd	CellCarta 2002, Montreal (Canada), Acquired	CRO focused on providing histopathology and genomics services	$7.5M	Waters Corporation, Great Point Partners & 5 others	62/100
3rd	Invivyd 2022, Waltham (United States), Public	Provider of drug research & development targets stem cell and clinical trial services	-	Bain Capital Life Sciences, Foresite Capital ... & 3 others	54/100
4th	Shanghai Cell Therapy Group 2014, Shanghai (China), Series D	Provider of cell-therapy focused research and development services	$202M	CCB International, Jiuzhou Venture Capital ... & 7 others	50/100
5th	Kincell Bio 2023, Gainesville (United States), Series A	Provider of clinical cell therapy development & manufacturing and consulting services	$58M	NewSpring, Kineticos	49/100
6th	GC Green Cross Lab Cell 2008, Yongin si (South Korea), Funding Raised	Provider of research, development, and manufacturing services for cell & gene therapy products	-	-	44/100
7th	CCRM 2011, Toronto (Canada), Unfunded	Developer of regenerative medicines	-	-	42/100
8th	XDemics 2017, Monrovia (United States), Series B	CDMO focused on manufacturing cell & viral based therapeutics	$14.8M	-	42/100
9th	Impel Pharmaceuticals 2008, Seattle (United States), Acquired	Provider of trans-formative therapy development and commercialisation services	$67.5M	Norwest, KKR & 4 others	41/100
10th	BioBridge Global 1974, San Antonio (United States), Unfunded	Manufacturer of cell and gene therapy clinical product & testing services	-	-	40/100
15th	Ascend 2021, London (United Kingdom), Series A	Provider of drug research & development and clinical trial services for cell & gene therapeutic services	$132M	Deerfield, Abingworth & 7 others	36/100